Aardvark Therapeutics: reports exploratory HERO and OLE trial data

What happened

• On Oct 23, 2026, Aardvark Therapeutics, Inc. issued a press release reporting exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (“HERO”) trial and open-label extension (“OLE”) trial. The press release is filed as Exhibit 99.1 to the Form 8-K.
• On Oct 23, 2026 at 8:00 a.m. ET, the company hosted an investor webinar to discuss the HERO and OLE data and filed the presentation used in the webinar as Exhibit 99.2; the presentation is current as of Oct 23, 2026 and the company disclaims any obligation to update it.

Key details

• Item reported: 8.01 Other events (press release and webinar discussing trial data).
• Exhibits filed: 99.1 Press Release dated Oct 23, 2026; 99.2 Presentation — HERO/OLE update webinar dated Oct 23, 2026.
• The press release and presentation relate to exploratory efficacy data from the previously terminated Phase 3 HERO trial and the OLE trial.
• The Form 8-K is signed by Tien-Li Lee, M.D., Chief Executive Officer, dated Oct 23, 2026.

Why it may matter

• The filing reports Item 8.01, which covers the company issuing a press release reporting exploratory efficacy data from the terminated Phase 3 HERO trial and the OLE trial and hosting a webinar; it also files the related materials as exhibits. This filing does not show why the insider traded or why the company acted.